Amgen Inc., the Thousand Oaks biotech giant, said Sunday a new study has found its cancer drug Kyprolis is far more effective in treatment of relapsed multiple myeloma than its chief rival.
Stuart Pfeifer, Los Angeles Times: Business
Sun, 03/01/2015 - 6:12pm
Amgen Inc., the Thousand Oaks biotech giant, said Sunday a new study has found its cancer drug Kyprolis is far more effective in treatment of relapsed multiple myeloma than its chief rival.